Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

Published:2017-11 Issue:11 Volume:18 Page:1454-1466
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Wu Yi-Long,Cheng Ying,Zhou Xiangdong,Lee Ki Hyeong,Nakagawa Kazuhiko,Niho Seiji,Tsuji Fumito,Linke Rolf,Rosell Rafael,Corral Jesus,Migliorino Maria Rita,Pluzanski Adam,Sbar Eric I,Wang Tao,White Jane Liang,Nadanaciva Sashi,Sandin Rickard,Mok Tony S

Publisher

Elsevier BV

Subject

Oncology

Reference32 articles.

1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

2. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

3. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China;Wu;J Thorac Oncol,2007

4. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

5. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

Cited by 924 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthetic routes and clinical application of Small-Molecule HER2 inhibitors for cancer therapy;Bioorganic Chemistry;2024-10

2. Novel Combination of Therapeutic Approaches in Advanced NSCLC with EGFR Activating Mutations;Targets;2024-09-07

3. Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study;Frontiers in Pharmacology;2024-09-06

4. Efficacy and Safety of Phosphatidylinositol 3-kinase Inhibitors for Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials;Current Cancer Drug Targets;2024-09

5. Targeting EGFR with molecular degraders as a promising strategy to overcome resistance to EGFR inhibitors;Future Medicinal Chemistry;2024-08-29